Cerebellum Gene Expression Correlates for VERCNT165 measured in BXD RI Females & Males obtained using SJUT Cerebellum mRNA M430 (Mar05) RMA. The VERCNT165 measures Morphine vertical activity counts minutes 150-165 under the domain Morphine. The correlates were thresholded at a p-value of less than 0.001.
Authors:
Philip VM, Duvvuru S, Gomero B, Ansah TA, Blaha CD, Cook MN, Hamre KM, Lariviere WR, Matthews DB, Mittleman G, Goldowitz D, Chesler EJ
Cerebellum Gene Expression Correlates for VERCNT165 measured in BXD RI Males obtained using SJUT Cerebellum mRNA M430 (Mar05) RMA. The VERCNT165 measures Morphine vertical activity counts minutes 150-165 under the domain Morphine. The correlates were thresholded at a p-value of less than 0.001.
Authors:
Philip VM, Duvvuru S, Gomero B, Ansah TA, Blaha CD, Cook MN, Hamre KM, Lariviere WR, Matthews DB, Mittleman G, Goldowitz D, Chesler EJ
Cerebellum Gene Expression Correlates for VERCNT180 measured in BXD RI Females & Males obtained using SJUT Cerebellum mRNA M430 (Mar05) RMA. The VERCNT180 measures Morphine vertical activity counts minutes 165-180 under the domain Morphine. The correlates were thresholded at a p-value of less than 0.001.
Authors:
Philip VM, Duvvuru S, Gomero B, Ansah TA, Blaha CD, Cook MN, Hamre KM, Lariviere WR, Matthews DB, Mittleman G, Goldowitz D, Chesler EJ
Cerebellum Gene Expression Correlates for VERCNT180 measured in BXD RI Males obtained using SJUT Cerebellum mRNA M430 (Mar05) RMA. The VERCNT180 measures Morphine vertical activity counts minutes 165-180 under the domain Morphine. The correlates were thresholded at a p-value of less than 0.001.
Authors:
Philip VM, Duvvuru S, Gomero B, Ansah TA, Blaha CD, Cook MN, Hamre KM, Lariviere WR, Matthews DB, Mittleman G, Goldowitz D, Chesler EJ
QTL for differences in cocaine responsiveness on Chr17 at DI7Mft3 (64.20 Mbp , Build 37)
Description:
differences in cocaine responsiveness spans 39.20 - 89.20 Mbp (NCBI Build 37) on Chr17. This interval was obtained by using an interval width of 25 Mbp around the peak marker (Build 37, MGI, http://informatics.jax.org).
QTL for METH responses for home cage activity on Chr17 at D17Mit3 (70.84 Mbp , Build 37)
Description:
METH responses for home cage activity spans 45.84 - 95.84 Mbp (NCBI Build 37) on Chr17. This interval was obtained by using an interval width of 25 Mbp around the peak marker (Build 37, MGI, http://informatics.jax.org).
QTL for METH responses for chewing on Chr17 at Hprt-ps1 (77.06 Mbp , Build 37)
Description:
METH responses for chewing spans 52.06 - 102.06 Mbp (NCBI Build 37) on Chr17. This interval was obtained by using an interval width of 25 Mbp around the peak marker (Build 37, MGI, http://informatics.jax.org).
QTL for nicotine sensitivity on Chr17 at D17Mit76 (84.11 Mbp , Build 37)
Description:
nicotine sensitivity spans 59.11 - 109.11 Mbp (NCBI Build 37) on Chr17. This interval was obtained by using an interval width of 25 Mbp around the peak marker (Build 37, MGI, http://informatics.jax.org).
QTL for nicotine sensitivity on Chr17 at D17Mit221 (86.51 Mbp , Build 37)
Description:
nicotine sensitivity spans 61.51 - 111.51 Mbp (NCBI Build 37) on Chr17. This interval was obtained by using an interval width of 25 Mbp around the peak marker (Build 37, MGI, http://informatics.jax.org).
QTL associated with bone response to mechanical loading 6. This interval was obtained by using a fixed interval width of 25 Mbp around the peak marker (74149996)
QTL associated with circulating hormone level QTL 9. This interval was obtained by using a fixed interval width of 25 Mbp around the peak marker (68800770)
QTL associated with nicotine induced locomotor activity 11. This interval was obtained by using a fixed interval width of 25 Mbp around the peak marker (90487044)
QTL associated with nicotine induced locomotor activity 12. This interval was obtained by using a fixed interval width of 25 Mbp around the peak marker (86033231)
QTL associated with colon tumor susceptibility 4. This interval was obtained by using a fixed interval width of 25 Mbp around the peak marker (79392921)
Authors:
Ruivenkamp CA, Csiks T, Klous AM, van Wezel T, Demant P
GeneWeaver